Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,408 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 1:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accuracy of Pulse Oximeters in Profound Hypoxia

NCT05920278
View directory record Official record
Conditions
Hypoxia
Interventions
Pulse oximeter
Device
Lead sponsor
Movano Health
Industry
Eligibility
18 Years to 49 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.

NCT01607385
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, GSK1614235
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Anti-MAG First Administration to Human

NCT00622609
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 27, 2026, 1:19 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

NCT07736638
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-859, Placebo for ABBV-859
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

NCT01281111
View directory record Official record
Conditions
Healthy
Interventions
Dimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

NCT00198458
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

NCT01950403
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease
Interventions
linaclotide acetate, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 27, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

NCT02213029
View directory record Official record
Conditions
Embryo Transfer
Interventions
Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers

NCT01592331
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO5508887
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

NCT01827657
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

NCT00247572
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Oct 27, 2026, 1:19 AM EDT
Completed No phase listed Observational

Magnetic Resonance Spectroscopy to Evaluate Tourette s Syndrome

NCT00030953
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
14 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

NCT02872428
View directory record Official record
Conditions
Shock,Hemorrhagic, Trauma
Interventions
Valproic Acid, Isotonic saline solution
Drug
Lead sponsor
Dr. Hasan Alam
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 27, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

NCT01794078
View directory record Official record
Conditions
Acute Mountain Sickness and Fatigue
Interventions
Aminophylline 400 mg, Ambrisentan 5 mg, Placebo
Drug · Other
Lead sponsor
Robert J Noveck, M.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 27, 2026, 1:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Stress Hormones on Emotion and Cognition

NCT00032838
View directory record Official record
Conditions
Healthy
Interventions
Yohimbine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects

NCT00935025
View directory record Official record
Conditions
Healthy
Interventions
AZD1305, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 27, 2026, 1:19 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Do Therapy Dogs Improve Behavior and Reduce Anxiety in Pediatric Dental Patients?

NCT06057090
View directory record Official record
Conditions
Therapy Animals, Dental Anxiety, Child Behavior, Anesthesia, Local
Interventions
Therapy Dog
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Years to 7 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

NCT00785915
View directory record Official record
Conditions
Healthy
Interventions
AZD6765, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Family Mediation Program For At-Risk Youth

NCT01944748
View directory record Official record
Conditions
Family Functioning
Interventions
Families Able To Resolve Situations (FARS)
Behavioral
Lead sponsor
RAND
Other
Eligibility
12 Years to 19 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Hawthorne, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 27, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

NCT02530710
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 27, 2026, 1:19 AM EDT